Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

About this trial

Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material);

no IDRF;

low or moderate risk group according to pilot difficulty scoring system (less than 5 points);

patients with any number of IDRFs and without central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.

Disqualifiers

3 and more IDRF + central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.

Severe concomitant pathology, increasing anesthesiologic and surgical risks, via the desicion of the research physician or conclusion by multidisciplinary team in centers- participants.

Tumor volume does not technically allow to provide minimally-invasive surgery, based on the conclusion of multidisciplinary experts board team in centers- participants.

Therapy strategy: observation

Trial population

Patients with abdominal neurogenic tumors in 0-18 years of age

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Duration of surgery intervention

    Procedure/Surgery

    Intraoperative- duration from the beginning of the skin incision to skin suture (min)

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Duration of surgery intervention

Pilot difficulty scoring system for laparoscopic surgery in abdominal neuroblastoma

Time frame
Intraoperative

Secondary outcomes

1

The influence of surgical risk factors

The influence of surgical risk factors (see supplementary material) on the surgery results (see supplementary material) and the course of the postoperative period.

Time frame
Intraoperative and 30 days postoperative
2

Cases of conversion from laparoscopic to cavity access

Time frame
Intraoperative
3

Comparison of surgeon's visual assessment of the tumor resection

Comparison of surgeon's visual assessment of the tumor resection completeness with data from abdominal contrast-enhanced CT, performed in the first 5 days after surgery.

Time frame
5 days postoperative
4

1-, 3-, 5-years local recurrence-free survival

Time frame
up to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.